- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Zejula.
Displaying page 1 of 2.
| EudraCT Number: 2020-005918-17 | Sponsor Protocol Number: 69HCL20_0989 | Start Date*: 2021-03-30 | |||||||||||
| Sponsor Name:Hospices Civils de Lyon | |||||||||||||
| Full Title: Study of how patient pharmacocinetic covariates influence toxicological events of niraparib as ovarian cancer treatment NIRAPK | |||||||||||||
| Medical condition: Ovarian, tubular or peritoneal high-grade epithelial carcinoma, histologically proven. Recommendation of a maintenance treatment with Niraparib at standard dose (200-300mg/day) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-004147-24 | Sponsor Protocol Number: 32018 | Start Date*: 2019-07-11 | |||||||||||
| Sponsor Name:DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO | |||||||||||||
| Full Title: A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Care as Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress Afte... | |||||||||||||
| Medical condition: locally non-resectable or metastatic local urothelial transitional tumor (transitional cell carcinoma both with pure and mixed histology). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-004623-36 | Sponsor Protocol Number: MEGALiT1901 | Start Date*: 2019-11-29 |
| Sponsor Name:Uppsala University Hospital | ||
| Full Title: A MolEcularly Guided Anti-Cancer Drug Off-Label Trial – a multicenter, basket and umbrella explorative trial on the efficacy and safety of molecular profile selected commercially available targete... | ||
| Medical condition: In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-003702-27 | Sponsor Protocol Number: P170929J | Start Date*: 2021-04-12 |
| Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
| Full Title: Phase II clinical trial aiming at investigating the effect of a PARP-inhibitor on advanced metastatic breast cancer in germline PALB2 mutations carriers | ||
| Medical condition: Patients with HER2 positive disease. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-003042-20 | Sponsor Protocol Number: ET21-169 | Start Date*: 2022-06-21 |
| Sponsor Name:Centre Léon Bérard | ||
| Full Title: PARPi-PANC - A multicentric, single arm, phase II trial assessing the efficacy of niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer | ||
| Medical condition: Patients with metastatic homologous repair-deficient pancreatic cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-004188-25 | Sponsor Protocol Number: ASST_FARM_ONCO_P-ACC_2022 | Start Date*: 2023-03-03 | ||||||||||||||||||||||||||
| Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | ||||||||||||||||||||||||||||
| Full Title: P-ACC Trial - Phase II, single arm, multicenter, open-label study of PARP inhibitors + cisplatin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma | ||||||||||||||||||||||||||||
| Medical condition: patients with recurrent and/or Metastatic Adenoid Cystic Carcinoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2019-004771-40 | Sponsor Protocol Number: ML41742 | Start Date*: 2020-04-28 | |||||||||||
| Sponsor Name:Rigshospitalet | |||||||||||||
| Full Title: ProTarget A Danish Nationwide Clinical Trial on Targeted Anti-Cancer Treatment based on Genomic Profiling | |||||||||||||
| Medical condition: Eligible patients will have an advanced malignant disease for which standard treatment options are no longer available or feasible and acceptable performance status and organ function. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004700-56 | Sponsor Protocol Number: N16OPE | Start Date*: 2017-06-30 | |||||||||||
| Sponsor Name:NKI-AVL | |||||||||||||
| Full Title: Exploratory study of neo-adjuvant treatment with carboplatin, paclitaxel and pembrolizumab in primary stage IV serous ovarian cancer | |||||||||||||
| Medical condition: Primary stage IV high-grade serous ovarian, peritoneal, or fallopian tube cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000109-10 | Sponsor Protocol Number: UNITO-001/2020 | Start Date*: 2020-09-30 | ||||||||||||||||
| Sponsor Name:DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO | ||||||||||||||||||
| Full Title: A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive fo... | ||||||||||||||||||
| Medical condition: patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germ or somatic mutations in DNA damage repair genes | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-004367-12 | Sponsor Protocol Number: FCR173009 | Start Date*: 2019-10-02 | ||||||||||||||||
| Sponsor Name:Fundación CRIS de investigación para vencer el cáncer | ||||||||||||||||||
| Full Title: A phase I-II study to evaluate the efficacy and safety of niraparib in combination with cabozantinib (XL184) in patients with advanced urothelial cancer after failure to first-line platinum-based c... | ||||||||||||||||||
| Medical condition: Urinary tract or renal cell carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-000146-33 | Sponsor Protocol Number: MITO33 | Start Date*: 2020-10-09 | |||||||||||||||||||||
| Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||||||||||||
| Full Title: Randomized phase III trial on NIraparib-TSR-042 (dostarlimab) vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platin... | |||||||||||||||||||||||
| Medical condition: Recurrent ovarian, fallopian tube or primary peritoneal cancer. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) GR (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2017-004323-72 | Sponsor Protocol Number: MedOPP190 | Start Date*: 2020-02-05 | |||||||||||||||||||||
| Sponsor Name:Medica Scientia Innovation Research (MedSIR) | |||||||||||||||||||||||
| Full Title: Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib plus Aromatase Inhibitors for Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor... | |||||||||||||||||||||||
| Medical condition: Advanced or metastatic HR-positive/HER2-negative breast cancer in patients harboring either gBRCAms or gBRCAwt and HRD. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2019-004875-38 | Sponsor Protocol Number: PRIMEH&N | Start Date*: 2020-11-12 | |||||||||||||||||||||
| Sponsor Name:Fondazione GONO | |||||||||||||||||||||||
| Full Title: The induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
| Medical condition: HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2021-004278-76 | Sponsor Protocol Number: GINECO-OV129b | Start Date*: 2021-11-22 | |||||||||||
| Sponsor Name:ARCAGY-GINECO | |||||||||||||
| Full Title: A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With... | |||||||||||||
| Medical condition: Advanced ovarian, tubal or peritoneal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-000952-11 | Sponsor Protocol Number: PR-30-5017-C | Start Date*: 2016-07-01 | |||||||||||
| Sponsor Name:TESARO, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Base... | |||||||||||||
| Medical condition: Homologous recombination deficiency advanced ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FI (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-002667-53 | Sponsor Protocol Number: 213409 | Start Date*: 2021-08-23 | |||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||||||||||||
| Full Title: An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and are Judged by the Investigator to Benefit... | |||||||||||||||||||||||
| Medical condition: advanced ovarian, breast, or prostate cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: AT (Trial now transitioned) FR (Trial now transitioned) DK (Completed) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2017-004058-40 | Sponsor Protocol Number: EUDARIO | Start Date*: 2018-10-16 |
| Sponsor Name:Katholieke Universiteit Leuven | ||
| Full Title: A multicentre, open-label, three-arm randomised Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin followed by maintenance treatment ... | ||
| Medical condition: Platinum-sensitive relapsed ovarian cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: BE (Completed) DE (Completed) FR (Completed) AT (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-004414-35 | Sponsor Protocol Number: IMPRESSNorway | Start Date*: 2021-02-19 |
| Sponsor Name:Oslo University Hospital | ||
| Full Title: Improving public cancer care by implementing precision medicine in Norway | ||
| Medical condition: Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-005392-39 | Sponsor Protocol Number: 213357 | Start Date*: 2022-02-25 | ||||||||||||||||
| Sponsor Name:GlaxoSmithKline, S.A. | ||||||||||||||||||
| Full Title: OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL). C... | ||||||||||||||||||
| Medical condition: Ovarian cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) DK (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-002350-78 | Sponsor Protocol Number: ProBio | Start Date*: 2018-10-22 | ||||||||||||||||
| Sponsor Name:Karolinska Institutet | ||||||||||||||||||
| Full Title: ProBio: An outcome adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer | ||||||||||||||||||
| Medical condition: Patients with metastatic hormone-sensitive and castration-resistant prostate cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
| Trial protocol: SE (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
